Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CERC-002
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury
Details : CERC-002 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 02, 2020
Lead Product(s) : CERC-002
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rislenemdaz
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Cerecor
Deal Size : $22.1 million
Deal Type : Acquisition
Cerecor and Aevi Genomic Medicine Complete Merger
Details : Cerecor’s pipeline now includes six clinical-stage assets, accelerating the company’s transformation into a research organization focused on developing new medicines for unmet needs in rare diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 03, 2020
Lead Product(s) : Rislenemdaz
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Cerecor
Deal Size : $22.1 million
Deal Type : Acquisition
Lead Product(s) : Fasoracetam
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AEVI-001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 01, 2018
Lead Product(s) : Fasoracetam
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fasoracetam
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AEVI-001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 29, 2017
Lead Product(s) : Fasoracetam
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NFC-1
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD
Details : NFC-1 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 30, 2016
Lead Product(s) : NFC-1
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NFC-1
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NFC-1 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of DiGeorge Syndrome.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 12, 2016
Lead Product(s) : NFC-1
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NFC-1
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD
Details : NFC-1 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 19, 2016
Lead Product(s) : NFC-1
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MDGN201
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Medgenics Medical
Deal Size : Inapplicable
Deal Type : Inapplicable
TARGTEPO Treatment for Anemia in PD US Trial
Details : MDGN201 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Anemia-associated with Kidney Diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 10, 2015
Lead Product(s) : MDGN201
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Medgenics Medical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MDGN201
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Medgenics Medical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MDGN201 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Anemia-associated with Kidney Diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 04, 2015
Lead Product(s) : MDGN201
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Medgenics Medical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NFC-1
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Thomas Jefferson University | Children's Hospital of Philadelphia | Pearson Clinical Assessment
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NFC-1 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 10, 2014
Lead Product(s) : NFC-1
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Thomas Jefferson University | Children's Hospital of Philadelphia | Pearson Clinical Assessment
Deal Size : Inapplicable
Deal Type : Inapplicable